Studio per valutare la superiorità della combinazione di acasunlimab e pembrolizumab rispetto allo standard di cura docetaxel nel carcinoma polmonare non a piccole cellule (ABBIL1TY NSCLC-06)
Uno studio prospettico, in aperto, randomizzato, di fase 3 su acasunlimab (GEN1046) in combinazione con pembrolizumab rispetto a docetaxel in soggetti con carcinoma polmonare non a piccole cellule metastatico PD-L1 positivo dopo trattamento con un inibitore PD-1/PD-L1 e Chemioterapia contenente platino (ABBIL1TY NSCLC-06)
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The goal of this trial is to determine the efficacy and safety of acasunlimab (an experimental antibody also known as GEN1046 or DuoBody® PDL1x4-1BB) in combination with pembrolizumab (an antibody known as KEYTRUDA®) compared to that of docetaxel (a standard of care chemotherapy). During the trial, the participant's quality of life will also be evaluated using industry-standard scales of measurement. To be eligible, participants must have:
- non-small cell lung cancer that are locally advanced, unresectable stage IIIB/C or has metastasized (spread)
- tumors that are positive for the PD-L1 protein (a biomarker that may be predictive of response to therapy)
- been previously treated with a PD-1/PD-L1-inhibitor and a platinum-containing cancer therapy administered in combination or sequentially (irrespective of the order).
Other eligibility criteria will also apply.
Participants will be assigned to 1 of 2 active therapies, also known as treatment arms, as follows:
- Acasunlimab (100 milligrams [mg]) and pembrolizumab (400 mg) once every 6 weeks (Q6W), or
- Docetaxel 75 milligrams per meter squared (mg/m^2) once every 3 weeks (Q3W).
The estimated trial duration for a participant will vary but may be up to 5 years, consisting of:
- An optional 3-month pre-screening period
- A 28-day screening period
- Up to 2 years of treatment
- A 90-day safety follow-up period
- Post-treatment follow-up.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Ciudad Autonoma Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires
-
La Rioja, Argentina
- Investigaciones CORI S.R.L.
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina
- Hospital Italiano de La Plata
-
Pergamino, Buenos Aires, Argentina
- Centro de Investigacion Pergamino S.A.
-
-
Ciudad Autonoma Buenos Aires
-
Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
- Instituto Medico Especializado Alexander Fleming
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina
- Sanatorio Parque S.A.
-
-
-
-
-
Fitzroy, Australia
- St Vincent's Hospital Melbourne
-
Wendouree, Australia
- Ballarat Oncology & Haematology Service
-
-
New South Wales
-
Camperdown, New South Wales, Australia
- Chris OBrien LifeHouse
-
Sydney, New South Wales, Australia
- Westmead Hospital
-
-
Queensland
-
Southport, Queensland, Australia
- Gold Coast Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australia
- Flinders Medical Centre
-
-
Western Australia
-
Perth, Western Australia, Australia
- Sir Charles Gairdner Hospital
-
Subiaco, Western Australia, Australia
- St John of God Subiaco Hospital
-
-
-
-
-
Linz, Austria
- Kepler Universitatsklinikum Med Campus III
-
Rankweil, Austria
- LKH - Rankweil
-
Vienna, Austria
- Standort Penzing der Klinik Ottakring
-
Vienna, Austria
- Wiener Gesundheitsverbund - Klinik Floridsdorf
-
-
-
-
-
Brussels, Belgio
- C. H. U. St-Pierre
-
Brussels, Belgio
- Universitair Ziekenhuis Bruxelles
-
Brussels, Belgio
- Cliniques Universitaires Saint-Luc
-
Gilly, Belgio
- Grand Hôpital de Charleroi
-
Hasselt, Belgio
- Jessa Ziekenhuis Hospital
-
Liège, Belgio
- CHU de Liège
-
Mechelen, Belgio
- AZ Sint-Maarten
-
Roeselare, Belgio
- AZ Delta
-
-
-
-
-
Belo Horizonte, Brasile
- Oncoclínicas do Brasil Serviços Médicos SA
-
Porto Alegre, Brasile
- Hospital Ernesto Dornelles
-
Rio de Janeiro, Brasile
- Oncoclínicas Rio de Janeiro
-
Santo André, Brasile
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
Paraná
-
Curitiba, Paraná, Brasile
- Hospital Erasto Gaertner
-
-
Pernambuco
-
Recife, Pernambuco, Brasile
- MultiHemo Servicos Medicos
-
-
Rio Do Janeiro
-
Rio de Janeiro, Rio Do Janeiro, Brasile
- Instituto D'Or Pesquisa e Ensino - Rio de Janeiro
-
-
Rio Grande Do Su
-
Porto Alegre, Rio Grande Do Su, Brasile
- Hospital São Lucas da PUCRS
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasile
- Hospital de Clinicas de Ijui
-
Porto Alegre, Rio Grande do Sul, Brasile
- Centro Gaucho Integrado - Mae de Deus Center
-
-
Santa Catarina
-
Itajaí, Santa Catarina, Brasile
- Clínica de Neoplasias Litoral Ltda.
-
-
São Paulo
-
São Paulo, São Paulo, Brasile
- BP A Beneficencia Portuguesa de Sao Paulo
-
São Paulo, São Paulo, Brasile
- Centro Paulista de Oncologia S.A.
-
São Paulo, São Paulo, Brasile
- Hospital Sirio-Libanes
-
-
-
-
-
Pleven, Bulgaria
- MHAT Heart and Brain - Pleven
-
Plovdiv, Bulgaria
- Complex Oncology Center - Plovdiv, EOOD
-
Sofia, Bulgaria
- UMHAT "Sv. Ivan Rilski", EAD
-
Sofia, Bulgaria
- MHAT for women's health - Nadezhda, OOD
-
Sofia, Bulgaria
- MHAT "Serdika", EOOD
-
Sofia, Bulgaria
- UMHAT 'SofiaMed', OOD
-
-
-
-
Ontario
-
Brampton, Ontario, Canada
- William Osler Health System-Brampton Civic Hospital|William Osler Health System
-
Kingston, Ontario, Canada
- Kingston Health Sciences Centre
-
Toronto, Ontario, Canada
- Princess Margaret Cancer Centre - University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada
- MUHC - Jewish General Hospital
-
-
-
-
-
Providencia, Chile
- FALP - Fundación Arturo López Pérez
-
Santiago, Chile
- Centro de Investigacion Clinica Bradford Hill
-
Santiago, Chile
- IRAM - Instituto de Radio Medicina
-
Viña del Mar, Chile
- Oncocentro APYS
-
-
-
-
-
Cheongju-si, Corea del Sud
- Chungbuk National University Hospital
-
Daegu, Corea del Sud
- Keimyung University Dongsan Hospital
-
Goyang-si, Corea del Sud
- National Cancer Center Korea
-
Seoul, Corea del Sud
- Asan Medical Center
-
Seoul, Corea del Sud
- Samsung Medical Center
-
Seoul, Corea del Sud
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Corea del Sud
- Ajou University Hospital
-
-
-
-
-
Dubrovnik, Croazia
- General Hospital Dubrovnik
-
Rijeka, Croazia
- Specialty Hospital Medico
-
Zagreb, Croazia
- Sestre milosrdnice University Hospital Center
-
Zagreb, Croazia
- Department for Pulmonary Diseases University Hospital Centre Zagreb
-
-
-
-
-
Tallinn, Estonia
- North Estonia Medical Centre Foundation
-
Tartu, Estonia
- Tartu University Hospital
-
-
-
-
-
Angers, Francia
- CHU Angers - Hôpital Larrey
-
Bayonne, Francia
- Centre Hospitalier de la côte Basque
-
Boulogne-Billancourt, Francia
- Hôpital Ambroise Paré
-
Créteil, Francia
- Centre Hospitalier Intercommunal de Creteil (CHIC)
-
Lille, Francia
- Hopital Albert Calmette - CHU Lille
-
Lyon, Francia
- Centre Léon Bérard
-
Marseille, Francia
- Assistance Publique-Hôpitaux de Marseille
-
Mulhouse, Francia
- CH de Mulhouse - Hôpital Emile Muller
-
Nantes, Francia
- Hôpital Privé du Confluent
-
Paris, Francia
- Institut Curie
-
Rennes, Francia
- CHU Rennes - Hopital Pontchaillou
-
Saint-Herblain, Francia
- ICO - Site René Gauducheau
-
Toulon, Francia
- Hôpital Sainte Musse
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Francia
- Institut Paoli Calmettes
-
-
Gironde
-
Bordeaux, Gironde, Francia
- Institut Bergonié
-
-
Paris
-
Paris, Paris, Francia
- Hopital Saint Joseph - Paris
-
-
Pyrenees Atlantiques
-
Bayonne, Pyrenees Atlantiques, Francia
- Clinique Belharra
-
-
Vaculuse
-
Avignon, Vaculuse, Francia
- Institut Sainte Catherine
-
-
Val de Marne
-
Villejuif, Val de Marne, Francia
- Institut Gustave Roussy
-
-
-
-
-
Hamburg, Germania
- Asklepios Klinik Harburg
-
-
Baden-Wurttemberg
-
Esslingen am Neckar, Baden-Wurttemberg, Germania
- Klinikum Esslingen GmbH
-
Heidelberg, Baden-Wurttemberg, Germania
- Thoraxklinik Heidelberg gGmbH
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Germania
- Universitaetsmedizin Goettingen
-
Hanover, Lower Saxony, Germania
- MHH Medizinische Hochschule Hannover
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Germania
- Johannes Gutenberg University Mainz
-
-
Saxony
-
Dresden, Saxony, Germania
- Universitatsklinikum Carl Gustav Carus Dresden
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Germania
- MVZ Martha-Maria Halle-Doelau
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germania
- LungenClinic Grosshansdorf GmbH
-
-
State of Berlin
-
Berlin, State of Berlin, Germania
- Vivantes Klinikum Neukoelln
-
Berlin, State of Berlin, Germania
- Evangelische Lungenklinik Berlin
-
Berlin, State of Berlin, Germania
- Vivantes Klinikum im Friedrichshain
-
Berlin, State of Berlin, Germania
- Vivantes Klinikum Spandau
-
-
-
-
-
Bunkyō City, Giappone
- Nippon Medical School Hospital
-
Chūōku, Giappone
- National Cancer Center Hospital
-
Fukuoka, Giappone
- NHO Kyushu Cancer Center
-
Hokkaido, Giappone
- NHO Hokkaido Cancer Center
-
Kurashiki-shi, Giappone
- Kurashiki Central Hospital
-
Kurume-shi, Giappone
- Kurume University Hospital
-
Kōtō City, Giappone
- Cancer Institute Hospital of JFCR
-
Nagoya, Giappone
- Aichi Cancer Center Hospital
-
Nagoya, Giappone
- NHO Nagoya Medical Center
-
Natori-shi, Giappone
- Miyagi Cancer Center
-
Okayama, Giappone
- Okayama University Hospital
-
Osaka, Giappone
- Osaka International Cancer Institute
-
Osaka, Giappone
- Osaka Medical and Pharmaceutical University Hospital
-
Ota-shi, Giappone
- Gunma Prefectural Cancer Center
-
Yokohama, Giappone
- Kanagawa Cancer Center
-
-
Ehime
-
Matsuyama, Ehime, Giappone
- Shikoku Cancer Center
-
-
Fukuoka
-
Kitakyushu-shi, Fukuoka, Giappone
- JCHO Kyushu Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, Giappone
- Hiroshima University Hospital
-
-
Hyōgo
-
Kobe, Hyōgo, Giappone
- Kobe Minimally Invasive Cancer Center
-
-
Kumamoto
-
Kumamoto, Kumamoto, Giappone
- Saiseikai Kumamoto Hospital
-
-
Osaka
-
Osakasayama-shi, Osaka, Giappone
- Kindai University Hospital
-
-
Tokyo-To
-
Bunkyō City, Tokyo-To, Giappone
- Juntendo University Hospital
-
-
-
-
-
Athens, Grecia
- Alexandra General Hospital
-
Athens, Grecia
- University General Hospital Attikon
-
Athens, Grecia
- Henry Dunant Hospital Center
-
Heraklion, Grecia
- University General Hospital of Heraklion
-
Larissa, Grecia
- University General Hospital of Larissa
-
Thessaloniki, Grecia
- Interbalkan Hospital of Thessaloniki
-
Thessaloniki, Grecia
- Bioclinic Thessaloniki
-
-
-
-
-
Cork, Irlanda
- Cork University Hospital
-
Dublin, Irlanda
- St Vincent's University Hospital
-
Limerick, Irlanda
- University Hospital Limerick
-
Waterford, Irlanda
- Waterford Regional Hospital
-
-
Dublin
-
Dublin, Dublin, Irlanda
- Beaumont Hospital
-
Dublin, Dublin, Irlanda
- St James's Hospital
-
-
-
-
-
Bergamo, Italia
- ASST Papa Giovanni XXIII
-
Candiolo, Italia
- Istituto di Candiolo
-
Meldola, Italia
- IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST
-
Milan, Italia
- IRCCS Istituto Nazionale dei Tumori
-
-
Genova
-
Genova, Genova, Italia
- Istituto Nazionale per la Ricerca sul Cancro di Genova
-
-
Milano
-
Monza, Milano, Italia
- Fondazione IRCCS San Gerardo dei Tintori
-
Rozzano, Milano, Italia
- Istituto Clinico Humanitas
-
-
Napoli
-
Naples, Napoli, Italia
- AOU Università degli Studi della Campania "Luigi Vanvitelli"
-
-
Pordenone
-
Aviano, Pordenone, Italia
- IRCCS Centro di Riferimento Oncologico
-
-
Ravenna
-
Ravenna, Ravenna, Italia
- Ospedale Santa Maria delle Croci
-
-
Roma
-
Roma, Roma, Italia
- Regina Elena National Cancer Institute
-
Rome, Roma, Italia
- IRCCS Policlinico Universitario Agostino Gemelli
-
-
Torino
-
Orbassano, Torino, Italia
- AOU San Luigi Gonzaga
-
-
Verona
-
Verona, Verona, Italia
- CRC - Centro Ricerche Cliniche di Verona S.r.l.
-
-
-
-
-
Amsterdam, Olanda
- Antoni van Leeuwenhoek
-
Amsterdam, Olanda
- Amsterdam UMC Locatie VUMC
-
Harderwijk, Olanda
- St. Jansdal Ziekenhuis
-
Heerlen, Olanda
- Zuyderland Medisch Centrum - Heerlen
-
Leiden, Olanda
- Leiden University Medical Center
-
Nijmegen, Olanda
- Radboudumc
-
Rotterdam, Olanda
- Erasmus Medisch Centrum
-
Utrecht, Olanda
- Universitair Medisch Centrum Utrecht
-
Zwolle, Olanda
- Isala Zwolle
-
-
-
-
-
Koszalin, Polonia
- Szpital Wojewodzki im. Mikolaja Kopernika w Koszalinie
-
Krakow, Polonia
- Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
-
Lodz, Polonia
- Polish Mother's Memorial Hospital (Instytut Centrum Zdrowia Matki Polki)
-
Skorzewo, Polonia
- Aidport sp z o.o.
-
Warsaw, Polonia
- Instytut Gruzlicy i Chorob Pluc w Warszawie
-
Warsaw, Polonia
- Maria Sklodowska-Curie National Research Institute of Oncology (Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie)
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Porto Rico, 902
- Pan American Oncology Trials, LLC
-
San Juan, Puerto Rico, Porto Rico, 917
- Auxilio Mutuo Cancer Center
-
-
-
-
-
Coimbra, Portogallo
- Unidade Local de Saude de Coimbra E P E
-
Matosinhos Municipality, Portogallo
- Unidade Local de Saúde de Matosinhos, E.P.E. - Hospital Pedro Hispano
-
Porto, Portogallo
- Hospital CUF Porto
-
Setúbal, Portogallo
- Unidade Local de Saude da Arrabida E. P. E
-
-
-
-
-
London, Regno Unito
- Guy's Hospital
-
London, Regno Unito
- Barts Hospital
-
Manchester, Regno Unito
- The Christie Hospital
-
Nottingham, Regno Unito
- Nottingham University Hospitals City Campus
-
Plymouth, Regno Unito
- Derriford Hospital
-
-
Strathclyde
-
Glasgow, Strathclyde, Regno Unito
- Beatson West of Scotland Cancer Care
-
-
-
-
-
Madrid, Spagna
- Hospital Universitario HM Sanchinarro
-
Madrid, Spagna
- Facility name: Clínica Universidad de Navarra
-
Málaga, Spagna
- Hospital Quironsalud Malaga
-
Valencia, Spagna
- IVO - Instituto Valenciano de Oncologia
-
-
Alicante
-
Alicante, Alicante, Spagna
- Hospital General Universitario Dr. Balmis
-
-
Barcelona
-
Barcelona, Barcelona, Spagna
- Hospital Universitari Vall d'Hebron
-
L'Hospitalet de Llobregat, Barcelona, Spagna
- ICO l'Hospitalet
-
-
Córdoba
-
Córdoba, Córdoba, Spagna
- Hospital Universitario Reina Sofia
-
-
Girona
-
Girona, Girona, Spagna
- ICO Girona
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Spagna
- Complejo Hospitalario Universitario de Santiago CHUS
-
-
Las Palmas
-
Las Palmas de Gran Canaria, Las Palmas, Spagna
- Complejo Hospitalario Universitario Insular Materno-Infantil
-
-
Madrid
-
Madrid, Madrid, Spagna
- Hospital Universitario 12 de Octubre
-
Madrid, Madrid, Spagna
- Hospital General Universitario Gregorio Marañon
-
Pozuelo de Alarcón, Madrid, Spagna
- Hospital Universitario Quironsalud Madrid
-
-
Málaga
-
Marbella, Málaga, Spagna
- H.C. Hospitales S.L.
-
Málaga, Málaga, Spagna
- Hospital Universitario Virgen de la Victoria
-
-
Navarre
-
Pamplona, Navarre, Spagna
- Clinica Universidad de Navarra
-
-
Sevilla
-
Seville, Sevilla, Spagna
- Hospital Universitario Virgen Macarena
-
Seville, Sevilla, Spagna
- Hospital Universitario Virgen del Rocio
-
-
Valencia
-
Valencia, Valencia, Spagna
- Hospital Universitari i Politecnic La Fe
-
-
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85712
- Arizona Blood and Cancer Specialists
-
-
California
-
Los Angeles, California, Stati Uniti, 90089
- Usc Norris Comprehensive Cancer Center
-
Vallejo, California, Stati Uniti, 94589
- Kaiser Permanente Vallejo Medical Center
-
-
Florida
-
Ocala, Florida, Stati Uniti, 34474
- Ocala Oncology Center P.L.
-
Orlando, Florida, Stati Uniti, 32806
- Orlando Regional Medical Center
-
-
Georgia
-
Athens, Georgia, Stati Uniti, 30607
- University Cancer & Blood Center, LLC
-
Atlanta, Georgia, Stati Uniti, 30318
- Piedmont Cancer Institute Atlanta
-
Atlanta, Georgia, Stati Uniti, 30328
- Piedmont Cancer Institute - Sandy Springs (Atlanta) Office
-
Fayetteville, Georgia, Stati Uniti, 30214
- Piedmont Cancer Institute - Fayetteville Office
-
Newnan, Georgia, Stati Uniti, 30265
- Piedmont Cancer Institute - Newnan Office
-
Stockbridge, Georgia, Stati Uniti, 30281
- Piedmont Cancer Institute - Stockbridge Office
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96817
- Kaiser Foundation Hospitals
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46219
- Community Cancer Center East Medical Oncology Hematology
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Stati Uniti, 40202
- Norton Cancer Institute
-
Pikeville, Kentucky, Stati Uniti, 41501
- Pikeville Medical Center
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Grand Island, Nebraska, Stati Uniti, 68803
- St. Francis Hospital - Grand Island
-
Omaha, Nebraska, Stati Uniti, 68124
- Oncology Hematology West
-
Omaha, Nebraska, Stati Uniti, 68130
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New York
-
Stony Brook, New York, Stati Uniti, 11790
- Stony Brook University Medical Center|University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Novant Health Pharmacy
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Novant Health Oncology Specialists
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania Health System
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Allegheny General Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Avera Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Parkridge Medical Center
-
Knoxville, Tennessee, Stati Uniti, 37920
- University of Tennessee Medical Center Cancer Institute
-
Nashville, Tennessee, Stati Uniti, 37205
- Tennessee Oncology
-
Nashville, Tennessee, Stati Uniti, 37203
- Midtown Tennessee Oncology
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Texas Oncology-Austin Midtown
-
Austin, Texas, Stati Uniti, 78731
- Texas Oncology-Austin Central
-
Austin, Texas, Stati Uniti, 78745
- South Austin Cancer Ctr
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- University of Virginia Hematology and Oncology
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Cancer Institute At Swedish Med Ctr
-
-
-
-
-
Douliu, Taiwan
- National Taiwan University Hospital Yunlin Branch
-
Tainan, Taiwan
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
Taipei, Taiwan
- National Taiwan University Cancer Center
-
Taoyuan City, Taiwan
- Chang Gung Memorial Hospital,Linkou
-
-
-
-
-
Adana, Turchia (Türkiye)
- Adana City Hospital
-
Adana, Turchia (Türkiye)
- Medical Park Seyhan Hospital
-
Ankara, Turchia (Türkiye)
- Gulhane Training and Research Hospital
-
Ankara, Turchia (Türkiye)
- Ankara City Hospital
-
Ankara, Turchia (Türkiye)
- Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Ankara, Turchia (Türkiye)
- Liv Hospital Ankara
-
Istanbul, Turchia (Türkiye)
- Goztepe Prof. Dr. Suleyman Yalcin City Hospital
-
Istanbul, Turchia (Türkiye)
- Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
-
Izmir, Turchia (Türkiye)
- İ.E.Ü. Medicalpoint İzmir Hastanesi
-
-
-
-
-
Budapest, Ungheria
- Orszagos Koranyi Pulmonologiai Intezet
-
Kecskemét, Ungheria
- Bács-Kiskun County Hospital BKMK
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
Participant has histologically or cytologically confirmed locally advanced (unresectable stage IIIB/C) or metastatic NSCLC (stage IV) with known subtype.
-
Participant has progressed radiographically on or after receiving:
- One prior line of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy concomitantly) in the locally advanced (unresectable stage IIIB/C) or metastatic disease setting; OR
- No more than 2 prior lines of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy sequentially, irrespective of the order) in the locally advanced (unresectable stage IIIB/C) or metastatic disease setting.
-
Participant must have positive tumor PD-L1 expression (tumor cells ≥1%) determined prospectively on a tumor sample from the locally advanced (unresectable stage IIIB/C) or metastatic setting at a sponsor-designated central laboratory.
-
Participant has measurable disease according to RECIST v1.1 as assessed by the investigator at baseline.
-
Participant has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days of Cycle 1 Day 1.
-
Participant has a life expectancy of ≥3 months.
-
Participant must have adequate organ and bone marrow function, per laboratory test results within 7 days of trial treatment.
Key Exclusion Criteria:
-
Documentation of known targetable epidermal growth factor receptor (EGFR) sensitizing mutations, anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET), ROS proto-oncogene 1; receptor tyrosine kinase (ROS1) rearrangement, Kirsten rat sarcoma virus (KRAS), B-Raf proto-oncogene (BRAF) mutations, and MET proto-oncogene; receptor tyrosine kinase (MET) exon 14 skipping mutations/MET amplification. NOTE: MET amplification testing is optional based on local availability of the test.
- Participants with known KRAS/BRAF mutations are eligible for the trial if they do not have access to targeted therapies.
-
Participants with newly identified, untreated or unstable or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis.
-
Prior treatment with docetaxel for NSCLC.
-
Prior treatment with a 4-1BB (CD137) targeted agent, any type of antitumor vaccine, autologous cell immunotherapy, or any unapproved immunotherapy.
-
Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A
Acasunlimab, 100 mg and pembrolizumab, 400 mg will be administered via intravenous (IV) infusion, once every 6 weeks (Q6W) (Cycle length=42 days). |
IV infusion
Altri nomi:
IV infusion |
|
Comparatore attivo: Arm B
Docetaxel, 75 mg/m^2 will be administered via IV infusion, once every 3 weeks (Q3W) (Cycle length=21 days). |
IV infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: Up to approximately 5 years
|
OS is defined as the time from date of randomization to date of death due to any cause. |
Up to approximately 5 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di partecipanti con eventi avversi (EA)
Lasso di tempo: Dalla prima dose fino alla fine dello studio (circa 5 anni)
|
Dalla prima dose fino alla fine dello studio (circa 5 anni)
|
|
|
Tempo di interruzione del trattamento a causa di AE
Lasso di tempo: Dalla prima dose fino alla fine dello studio (circa 5 anni)
|
Dalla prima dose fino alla fine dello studio (circa 5 anni)
|
|
|
Concentrazione plasmatica di Acasunlimab
Lasso di tempo: Predose e postdose a più momenti temporali nei Cicli 1-4 (Durata del ciclo=42 giorni)
|
Predose e postdose a più momenti temporali nei Cicli 1-4 (Durata del ciclo=42 giorni)
|
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Up to approximately 5 years
|
PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause, whichever occurs first based on response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator. |
Up to approximately 5 years
|
|
Confirmed Overall Response Rate (ORR)
Lasso di tempo: Up to approximately 5 years
|
Confirmed ORR is defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 5 years
|
|
Duration of Response (DOR)
Lasso di tempo: Up to approximately 5 years
|
DOR is defined as the time from the onset date of response to the date of the first documented progression or death due to any cause based on RECIST v1.1 as assessed by the investigator. |
Up to approximately 5 years
|
|
Number of Participants With Anti-drug Antibodies (ADAs) to Acasunlimab
Lasso di tempo: Predose and postdose at multiple timepoints in Cycles 1-4 (Cycle length=42 days)
|
Serum samples will be analyzed using validated, specific, and sensitive immunoassay method. Samples will be screened for ADAs binding to acasunlimab and the titer of confirmed positive/negative samples will be reported. |
Predose and postdose at multiple timepoints in Cycles 1-4 (Cycle length=42 days)
|
|
Change From Baseline in Functional Assessment of Cancer Therapy Item GP5 (FACIT-GP5; Version 4) Score
Lasso di tempo: Baseline up to approximately 2 years
|
Participant's global assessment of treatment tolerability will be assessed by FACIT-GP5. FACIT-GP5 asks participants to rate their agreement with the following statement, "I am bothered by side effects of treatment" in the past 7 days. Responses will be captured on a 5-point Likert scale ranging from 0 to 4 indicating 0 as not at all to 4 as very much bothered by side effects. |
Baseline up to approximately 2 years
|
|
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Lasso di tempo: Up to approximately 2 years
|
The PRO-CTCAE allows participants to report on the frequency, severity, and interference of patient-reported symptoms. For each AE, there are between one and three items to assess the frequency, severity, and/or interference with activities related to that AE. All PRO-CTCAE responses will be scored from 0 to 4 for frequency indicating (0= never to 4= almost constantly), severity (0= none to 4= very severe) and interference with usual or daily activities (0= not at all to 4= very much). |
Up to approximately 2 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Study Official, Genmab
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Prodotti chimici organici
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Taxoidi
- Ciclodecani
- Diterpenes
- Docetaxel
- pembrolizumab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- GCT1046-06
- 2024-512998-27-00 (Ctis)
- jRCT2051240178 (Identificatore di registro: Japan Registry of Clinical Trials)
- 1010602 (Identificatore di registro: UK Research Summary Database)
- NL-OMON57246 (Identificatore di registro: NL CCMO)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .